AB1246 SOCIOECONOMIC STATUS, WORK IMPAIRMENT, DISABILITY AND SEVERITY OF GOUT IN LATIN AMERICA (LAT)
Authors: J. Vazquez Mellado, G. Da Rocha Castelar Pinheiro, J. E. Navarro-Zarza, C. Pineda, G. Sequeira, C. Elera-Fitzcarrald, M. Vázquez-Del Mercado Espinosa, K. De la Cruz Rodriguez, C. Gómez-Ruiz, S. Guzman Garcia, A. Gaffo, E. Garay, A. Tafoya
Journal: Annals of the Rheumatic Diseases (2023)

<h3>Background</h3> Previous reports suspected that gout patients from Latin-América (LAT) are different to those from developed countries and similar to Asian. <h3>Objectives</h3> We aimed to characterize patients with gout attending to Rheumatologists at Health public institutions and private practices in LAT and its association with socioeconomic status and clinical severity. <h3>Methods</h3> This cross-over, multi-centric, multinational and descriptive study was performed between 2019 and 2022. We invited to participate ≈150 certified rheumatologists from 14 countries in LAT. The project was authorized by IRB. Gout (ACR-EULAR 2015) patients signed informed consent. During face to face and on-line interviews, we discussed clinical variables (≈200), questionnaires and CRFs in Spanish and Portuguese. Demographics, socioeconomic status: (AMAI &lt;111= low socioeconomic status), clinical gout, associated diseases and treatment related variables were included. We defined severe gout (SG) if ≥5 tophi and/or intradermal tophi. Metabolic syndrome (MS: ≥ 3, ATP3 definitions and criteria). HAQ score, VAS for pain and general health and EuroQoL: EQ5D were obtained during regular visit to Rheumatologist. Data was sent and analyzed at GRESGO (Gout study group) coordination centre). Statistical analysis included mean SD, median, IQR, t test, x2, ANOVA. <h3>Results</h3> Fifty two rheumatologists from 11 countries in LAT sent the data of 500 gout patients. Males (95%), mean (SD): age 57(14), age at onset 41(13), educational level 10(4) and duration of the disease 14 (12) years. The clinical spectrum of gout was evaluated first in 3 groups: 1) <b>SG</b> (SG+MS-, n=78, 16%); 2) <b>MS</b> (MS+SG1-, n=218, 44%) and 3) <b>others</b> (gout: SG- and metabolic data ≤ 2 ATP criteria, n=204, 41%). Second analysis included comparison of extreme groups (SG VS MS) (Table 1). <h3>Conclusion</h3> LAT SG patients were different compared to MS gout ant others. SG are younger males from low educational and socioeconomic status, &gt;familial history of gout. As a consequence, SG patients also had aggressive and active poor controlled disease: &gt;flares, tophi number and size, more hospitalizations and lower quality of life: &gt;HAQ scores and more frequent alterations in the 5 EQ5D domains: (mobility, self-care, daily activities, pain, anxiety and depression) and disability consequences as work impairment. In the other hand, MS group had clearly more data associated to metabolic syndrome and higher cardiovascular risks. <b>Gout in LAT: SG vs MS comparison of demographics and clinical characteristics.</b> <h3>Acknowledgements</h3> on behalf of: Arias S, Granados Y, Silveira LH, Vazquez Mellado A, Altamirano A, Vargas A, Muñoz R, Medrano J, Estrada G, Fara N, Meza G, Maya L, Sandoval L, Hernández C, de Abreu P, Loya B, Ventura L, Guzman G, Ortega L, Alvarado V, Xibillé DX, Garrido E, Cruz L, Jiménez X, Reyes G, Castillo A, Mercado G, Azócar M, Santiago M, Duran S, Barbosa R, Fuentes M, Vargas AS, Lugo GE, Gamez G, Maldonado I, Gonzalez L, Zamora E, Hernández C, Lopez H, Pelaez I, Burgos Vargas R, Casasola J, Dominguez D, Alvarez E, Villanueva M. <h3>Disclosure of Interests</h3> None Declared.